<span item_type="fundamental" item_id="28d83e7b06bd81e4a9a2b1831a6f88ac" counter_id="ST/US/OACCU" env="prod"></span><span item_type="announcement" item_id="548613858106671873" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD 0.08.</p><p></p><h3>Segment Revenue</h3><ul><li>The company has not generated any operating revenues as of June 30, 2025, and expects to generate non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2029769/000119312525178570/d940883d10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Income</strong>: For the three months ended June 30, 2025, net income was $1,874,343, and for the six months ended June 30, 2025, net income was $3,533,134.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2029769/000119312525178570/d940883d10q.htm"></span></li><li><strong>General and Administrative Expenses</strong>: For the three months ended June 30, 2025, expenses were $269,810, and for the six months ended June 30, 2025, expenses were $714,612.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2029769/000119312525178570/d940883d10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow</strong>: Net cash used in operating activities for the six months ended June 30, 2025 was - $221,685.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2029769/000119312525178570/d940883d10q.htm"></span></li><li><strong>Investing Cash Flow</strong>: Cash flows from investing activities for the six months ended June 30, 2025 were $250,000.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2029769/000119312525178570/d940883d10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Interest Income</strong>: Interest earned on cash held in the Trust Account was $2,144,153 for the three months ended June 30, 2025, and $4,247,746 for the six months ended June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2029769/000119312525178570/d940883d10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company intends to effectuate its initial business combination using cash from the proceeds of its initial public offering and the sale of private placement units, as well as shares, debt, or a combination of cash, equity, and debt.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2029769/000119312525178570/d940883d10q.htm"></span></li><li><strong>Non-Core Business</strong>: The company has not commenced any operations and is focused on identifying a target company for a business combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2029769/000119312525178570/d940883d10q.htm"></span></li></ul>

Oaktree Acquisition Corp III Life Sciences - Unit | 10-Q: FY2025 Q2 EPS: USD 0.08